$TYRA
Tyra Biosciences, Inc.

2021 Q4 Form 10-Q Financial Statement

#000095017021002837 Filed on November 03, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.682M $1.154M $2.094M
YoY Change 28.08% 145.53%
% of Gross Profit
Research & Development $7.250M $5.484M $2.930M
YoY Change 147.44% 194.52%
% of Gross Profit
Depreciation & Amortization $50.00K $41.00M $19.00K
YoY Change 163.16% 156.25%
% of Gross Profit
Operating Expenses $9.932M $6.638M $9.297M
YoY Change 6.83% 184.65%
Operating Profit -$6.638M
YoY Change 184.65%
Interest Expense $5.000K $2.000K -$1.000K
YoY Change -600.0%
% of Operating Profit
Other Income/Expense, Net -$3.000K -$5.000K -$38.00K
YoY Change -92.11% -28.57%
Pretax Income -$9.930M -$6.643M -$9.336M
YoY Change 6.36% 184.01%
Income Tax
% Of Pretax Income
Net Earnings -$9.930M -$6.643M -$3.685M
YoY Change 169.47% 184.01%
Net Earnings / Revenue
Basic Earnings Per Share -$0.72
Diluted Earnings Per Share -$219.2K -$168.6K -$236.9K
COMMON SHARES
Basic Shares Outstanding 41.27M 10.62M
Diluted Shares Outstanding 9.164M

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $302.2M $312.8M
YoY Change
Cash & Equivalents $302.2M $312.8M $15.22M
Short-Term Investments
Other Short-Term Assets $1.875M $678.0K
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $304.1M $313.5M $15.28M
YoY Change 1889.77%
LONG-TERM ASSETS
Property, Plant & Equipment $1.027M $779.0K $297.0K
YoY Change 245.79%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $312.0K $318.0K $21.00K
YoY Change 1385.71%
Total Long-Term Assets $2.644M $2.469M $730.0K
YoY Change 262.19%
TOTAL ASSETS
Total Short-Term Assets $304.1M $313.5M $15.28M
Total Long-Term Assets $2.644M $2.469M $730.0K
Total Assets $306.7M $316.0M $16.01M
YoY Change 1815.56%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $599.0K $2.068M $664.0K
YoY Change -9.79%
Accrued Expenses $3.017M $2.700M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change
Total Short-Term Liabilities $3.616M $4.768M $1.858M
YoY Change 94.62%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $367.0K $434.0K $140.0K
YoY Change 162.14%
Total Long-Term Liabilities $367.0K $434.0K $140.0K
YoY Change 162.14%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.616M $4.768M $1.858M
Total Long-Term Liabilities $367.0K $434.0K $140.0K
Total Liabilities $4.964M $6.239M $1.998M
YoY Change 148.45%
SHAREHOLDERS EQUITY
Retained Earnings -$40.37M -$30.44M -$14.08M
YoY Change 186.79%
Common Stock $342.1M $340.2M $439.0K
YoY Change 77828.93%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $301.7M $309.7M -$13.64M
YoY Change
Total Liabilities & Shareholders Equity $306.7M $316.0M $16.01M
YoY Change 1815.56%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q4
OPERATING ACTIVITIES
Net Income -$9.930M -$6.643M -$3.685M
YoY Change 169.47% 184.01%
Depreciation, Depletion And Amortization $50.00K $41.00M $19.00K
YoY Change 163.16% 156.25%
Cash From Operating Activities -$9.028M -$5.578M -$2.530M
YoY Change 256.84% 163.74%
INVESTING ACTIVITIES
Capital Expenditures -$105.0K -$256.0K -$67.00K
YoY Change 56.72% 137.04%
Acquisitions
YoY Change
Other Investing Activities $0.00 $16.00K
YoY Change
Cash From Investing Activities -$105.0K -$240.0K -$67.00K
YoY Change 56.72% 122.22%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -1.508M 183.4M -4.000K
YoY Change 37600.0% -3057383.33%
NET CHANGE
Cash From Operating Activities -9.028M -5.578M -2.530M
Cash From Investing Activities -105.0K -240.0K -67.00K
Cash From Financing Activities -1.508M 183.4M -4.000K
Net Change In Cash -10.64M 177.6M -2.601M
YoY Change 309.11% -8068.55%
FREE CASH FLOW
Cash From Operating Activities -$9.028M -$5.578M -$2.530M
Capital Expenditures -$105.0K -$256.0K -$67.00K
Free Cash Flow -$8.923M -$5.322M -$2.463M
YoY Change 262.28% 165.17%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001863127
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
us-gaap Early Repayment Of Subordinated Debt
EarlyRepaymentOfSubordinatedDebt
CY2020Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
tyra Deferred Offering Costs Included In Accrued Expenses
DeferredOfferingCostsIncludedInAccruedExpenses
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40800
dei Entity Registrant Name
EntityRegistrantName
TYRA BIOSCIENCES, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
83-1476348
dei Entity Address Address Line1
EntityAddressAddressLine1
2656 State Street
dei Entity Address City Or Town
EntityAddressCityOrTown
Carlsbad
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92008
dei City Area Code
CityAreaCode
619
dei Local Phone Number
LocalPhoneNumber
728-4760
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
TYRA
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
No
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
41265756
dei Entity Listing Par Value Per Share
EntityListingParValuePerShare
0.0001
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
312823000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15224000
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
678000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
57000
CY2021Q3 us-gaap Assets Current
AssetsCurrent
313501000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
15281000
CY2021Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
243000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
243000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
779000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
297000
CY2021Q3 tyra Right Of Use Asset
RightOfUseAsset
1129000
CY2020Q4 tyra Right Of Use Asset
RightOfUseAsset
169000
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
318000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
21000
CY2021Q3 us-gaap Assets
Assets
315970000
CY2020Q4 us-gaap Assets
Assets
16011000
CY2021Q3 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
68000
CY2020Q4 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
0
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2068000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
664000
CY2021Q3 tyra Lease Liability Current
LeaseLiabilityCurrent
135000
CY2020Q4 tyra Lease Liability Current
LeaseLiabilityCurrent
142000
CY2021Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2565000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1052000
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
4768000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1858000
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1037000
CY2021Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
434000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
140000
CY2021Q3 us-gaap Liabilities
Liabilities
6239000
CY2020Q4 us-gaap Liabilities
Liabilities
1998000
CY2021Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
0
CY2020Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
27651000
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
0
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-14077000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
309731000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-13638000
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42535661
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3050781
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
41207660
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1829377
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
4000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
0
CY2021Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
340168000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
439000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-30441000
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
315970000
us-gaap Investment Income Interest
InvestmentIncomeInterest
8000
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
17000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-5000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
16011000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5484000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1862000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13386000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4275000
CY2021Q3 us-gaap Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party
RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
142000
CY2020Q3 us-gaap Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party
RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
0
us-gaap Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party
RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
260000
us-gaap Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party
RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
0
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1154000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
470000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2970000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1345000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
6638000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
2332000
us-gaap Operating Expenses
OperatingExpenses
16356000
us-gaap Operating Expenses
OperatingExpenses
5620000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6638000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2332000
us-gaap Operating Income Loss
OperatingIncomeLoss
-16356000
us-gaap Operating Income Loss
OperatingIncomeLoss
-5620000
CY2021Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
2000
CY2020Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
0
us-gaap Investment Income Interest
InvestmentIncomeInterest
1000
CY2021Q3 tyra Fair Value Adjustment Of Commitments
FairValueAdjustmentOfCommitments
0
CY2020Q3 tyra Fair Value Adjustment Of Commitments
FairValueAdjustmentOfCommitments
0
tyra Fair Value Adjustment Of Commitments
FairValueAdjustmentOfCommitments
0
tyra Fair Value Adjustment Of Commitments
FairValueAdjustmentOfCommitments
15000
CY2021Q3 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
7000
CY2020Q3 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
7000
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
16000
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-7000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-8000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-31000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-6643000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-2339000
us-gaap Net Income Loss
NetIncomeLoss
-16364000
us-gaap Net Income Loss
NetIncomeLoss
-5651000
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.72
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.47
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.63
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.83
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
9164003
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1594873
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4504997
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
108000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-6107000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-4741000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-1474000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
98000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1475266
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000
CY2021Q2 tyra Vesting Of Shares Of Common Stock Subject To Repurchase
VestingOfSharesOfCommonStockSubjectToRepurchase
28000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
338000
CY2021Q3 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
157274000
CY2021Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
181220000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-1838000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-7847000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
106000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-2339000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
-10080000
CY2020Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
127000
CY2020Q4 us-gaap Net Income Loss
NetIncomeLoss
-3685000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-13638000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-13638000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
86000
CY2021Q1 tyra Vesting Of Shares Of Common Stock Subject To Repurchase
VestingOfSharesOfCommonStockSubjectToRepurchase
65000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
174000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-4209000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-17522000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-5512000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-22667000
CY2021Q3 tyra Vesting Of Shares Of Common Stock Subject To Repurchase
VestingOfSharesOfCommonStockSubjectToRepurchase
39000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
507000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-6643000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
309731000
us-gaap Net Income Loss
NetIncomeLoss
-16364000
us-gaap Net Income Loss
NetIncomeLoss
-5651000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
90000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
28000
us-gaap Share Based Compensation
ShareBasedCompensation
1019000
us-gaap Share Based Compensation
ShareBasedCompensation
312000
tyra Fair Value Adjustment Of Commitments
FairValueAdjustmentOfCommitments
0
tyra Fair Value Adjustment Of Commitments
FairValueAdjustmentOfCommitments
15000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-3000
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
917000
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-18000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1396000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
59000
tyra Increase Decrease In Right Of Use Assets And Lease Liabilities Net
IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet
56000
tyra Increase Decrease In Right Of Use Assets And Lease Liabilities Net
IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet
-14000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14717000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5233000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
556000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
245000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
16000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-540000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-245000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
88000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
140000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
450000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
182729000
us-gaap Early Repayment Of Subordinated Debt
EarlyRepaymentOfSubordinatedDebt
25000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
9000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
13000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
312856000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
23438000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
297599000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
17960000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15467000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
108000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
313066000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18068000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
312823000
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18068000
CY2021Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
243000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
313066000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18068000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
17000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
44000
tyra Deferred Offering Costs Included In Accrued Expenses
DeferredOfferingCostsIncludedInAccruedExpenses
1509000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1238000
CY2021Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.025974
CY2021Q3 tyra Increase In Authorized Share Due To Forward Stock Split
IncreaseInAuthorizedShareDueToForwardStockSplit
50000000
CY2021Q3 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
0
CY2020Q4 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
0
CY2021Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
898000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
340000
CY2021Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
119000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
43000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
779000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
297000
CY2021Q3 us-gaap Depreciation
Depreciation
41000000
us-gaap Depreciation
Depreciation
90000000
CY2020Q3 us-gaap Depreciation
Depreciation
16000000
us-gaap Depreciation
Depreciation
28000000
CY2021Q3 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
634000
CY2020Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
774000
CY2021Q3 tyra Accrued Research And Development
AccruedResearchAndDevelopment
392000
CY2020Q4 tyra Accrued Research And Development
AccruedResearchAndDevelopment
163000
CY2021Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1356000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
67000
CY2021Q3 tyra Accrued Other General And Administrative Fees
AccruedOtherGeneralAndAdministrativeFees
183000
CY2020Q4 tyra Accrued Other General And Administrative Fees
AccruedOtherGeneralAndAdministrativeFees
48000
CY2021Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2565000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1052000
CY2021Q3 us-gaap Capital Units Authorized
CapitalUnitsAuthorized
550000000
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42535661
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3050781
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
41207660
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1829377
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2088932
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.42
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
877333
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.61
CY2021Q3 tyra Convertible Preferred Stock
ConvertiblePreferredStock
0
CY2020Q4 tyra Convertible Preferred Stock
ConvertiblePreferredStock
8765053
CY2021Q3 tyra Common Stock Options Granted And Outstanding
CommonStockOptionsGrantedAndOutstanding
2586313
CY2020Q4 tyra Common Stock Options Granted And Outstanding
CommonStockOptionsGrantedAndOutstanding
1374714
CY2021Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
14356313
CY2020Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
10168362
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1374714
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.61
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y4M24D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
292000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2586313
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.88
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y3M18D
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
38044000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
742432
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
1.25
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y10M24D
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
12128000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2573687
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
2.89
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P9Y3M18D
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
37841000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
600000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
17000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.70
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.47
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-6643000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.83
CY2021Q3 tyra Provision Related To Repurchase Of Early Exercised Options
ProvisionRelatedToRepurchaseOfEarlyExercisedOptions
749476
CY2020Q4 tyra Provision Related To Repurchase Of Early Exercised Options
ProvisionRelatedToRepurchaseOfEarlyExercisedOptions
230222
CY2021Q3 tyra Liability Related To Repurchase Of Early Exercised Options
LiabilityRelatedToRepurchaseOfEarlyExercisedOptions
400000
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.47
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.63
CY2020Q4 tyra Liability Related To Repurchase Of Early Exercised Options
LiabilityRelatedToRepurchaseOfEarlyExercisedOptions
100000
tyra Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Stock Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice
0.61
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
5400000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y9M18D
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-2339000
us-gaap Net Income Loss
NetIncomeLoss
-16364000
us-gaap Net Income Loss
NetIncomeLoss
-5651000
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10621868
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3052395
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5984285
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2927056
CY2021Q3 tyra Weighted Average Unvested Founder Shares Of Common Stock
WeightedAverageUnvestedFounderSharesOfCommonStock
-673607
CY2020Q3 tyra Weighted Average Unvested Founder Shares Of Common Stock
WeightedAverageUnvestedFounderSharesOfCommonStock
-1227301
tyra Weighted Average Unvested Founder Shares Of Common Stock
WeightedAverageUnvestedFounderSharesOfCommonStock
-785036
tyra Weighted Average Unvested Founder Shares Of Common Stock
WeightedAverageUnvestedFounderSharesOfCommonStock
-1345303
CY2021Q3 tyra Weighted Average Unvested Common Stock Issued Upon Exercise Of Common Stock Options
WeightedAverageUnvestedCommonStockIssuedUponExerciseOfCommonStockOptions
-784258
CY2020Q3 tyra Weighted Average Unvested Common Stock Issued Upon Exercise Of Common Stock Options
WeightedAverageUnvestedCommonStockIssuedUponExerciseOfCommonStockOptions
-230221
tyra Weighted Average Unvested Common Stock Issued Upon Exercise Of Common Stock Options
WeightedAverageUnvestedCommonStockIssuedUponExerciseOfCommonStockOptions
-694252
tyra Weighted Average Unvested Common Stock Issued Upon Exercise Of Common Stock Options
WeightedAverageUnvestedCommonStockIssuedUponExerciseOfCommonStockOptions
-106487
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
9164003
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1594873
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4504997
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1475266
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.72
CY2021Q3 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
0
CY2020Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
21000
CY2021Q3 tyra Right Of Use Asset
RightOfUseAsset
1129000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3954858
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5144712
CY2020Q4 tyra Right Of Use Asset
RightOfUseAsset
169000
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
135000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
133000
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1037000
CY2021Q3 us-gaap Finance Lease Liability
FinanceLeaseLiability
0
CY2020Q4 us-gaap Finance Lease Liability
FinanceLeaseLiability
9000
CY2021Q3 tyra Lease Liabilities
LeaseLiabilities
1172000
tyra Milestones Payments
MilestonesPayments
0
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1129000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
148000
CY2020Q4 tyra Lease Liabilities
LeaseLiabilities
142000
CY2021Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
124000
CY2020Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
27000
us-gaap Operating Lease Cost
OperatingLeaseCost
251000
us-gaap Operating Lease Cost
OperatingLeaseCost
76000
CY2021Q3 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
1000
CY2021Q3 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P0Y
CY2020Q4 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P0Y7M6D
CY2021Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0750
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
135000
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1037000
CY2021Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y9M18D
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P0Y9M18D
CY2020Q3 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
2000
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
5000
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
6000
CY2021Q3 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
0
CY2020Q3 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
0
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
0
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
1000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
20000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
277000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
299000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
308000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
318000
CY2021Q3 tyra Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
188000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1410000
CY2021Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
238000
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1172000
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0750
CY2021Q3 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.0750
CY2020Q4 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.0750

Files In Submission

Name View Source Status
0000950170-21-002837-index-headers.html Edgar Link pending
0000950170-21-002837-index.html Edgar Link pending
0000950170-21-002837.txt Edgar Link pending
0000950170-21-002837-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tyra-20210930.htm Edgar Link pending
tyra-20210930.xsd Edgar Link pending
tyra-20210930_cal.xml Edgar Link unprocessable
tyra-20210930_def.xml Edgar Link unprocessable
tyra-20210930_htm.xml Edgar Link completed
tyra-20210930_lab.xml Edgar Link unprocessable
tyra-20210930_pre.xml Edgar Link unprocessable
tyra-ex31_1.htm Edgar Link pending
tyra-ex31_2.htm Edgar Link pending
tyra-ex32_1.htm Edgar Link pending
tyra-ex32_2.htm Edgar Link pending